Google AI: EM board members are hired to 2 boards within Medtronic. With EM's involvement, which business units will be likely pushed to improve the profitability? any chance of spin off more business units?
AI generated answer:
In August 2025, after engagement with activist investor Elliott Investment Management (often abbreviated as "EM"), Medtronic appointed two independent directors
John Groetelaars and Bill Jellison and created two new board committees. These new committees will target profitability across all business units, and further spin-offs are a significant possibility.
The new directors' backgrounds point to a focus on operations and portfolio management:
- John Groetelaars is a veteran medtech executive with experience in mergers and acquisitions (M&A).
- Bill Jellison is a seasoned finance executive with a background in operational improvements.
Business units targeted for profitability improvements
The newly formed board committees—the Growth Committee and the Operating Committee—will apply scrutiny to all of Medtronic's business units. Based on past performance and strategic reviews, the following portfolios and divisions are most likely to be pressured for margin improvement:
- Medical Surgical Portfolio: This unit saw a decline in reported revenue in FY25 and only a modest organic increase. The Operating Committee will likely focus on improving efficiency within its global manufacturing, supply chain, and operations to boost margins.
- Specialty Therapies (within Neuroscience): This division experienced a decline in organic revenue in Q1 FY26, in part due to challenges like volume-based procurement in China. The new directors will likely push for a more effective strategy to address these market-specific headwinds.
- Cranial & Spinal Technologies (CST) (within Neuroscience): Although CST is generally a strong performer, the Growth Committee will look for opportunities to optimize its performance, possibly through more strategic tuck-in acquisitions or by better leveraging technology like the AiBLE™ spine surgery ecosystem.
Chance of more business unit spin-offs
The appointment of these new board members and the creation of the Growth Committee, which is explicitly tasked with evaluating "potential divestitures," significantly increase the probability of further spin-offs.
Evidence of activist influence: Medtronic's moves came after "constructive engagement with Elliott". Activist investors like Elliott Management are known for pressuring companies to sell or spin off underperforming or non-core assets to unlock shareholder value.
Successful model for spin-offs: The diabetes spin-off is a template for how Medtronic can create a more focused, higher-margin portfolio. It has already been deemed a successful strategy that improves margins and earnings per share.
Potential candidates: Any unit that underperforms on profitability or operates with a different business model could be a candidate for divestiture. This includes:
Less profitable parts of the Medical Surgical portfolio: If profitability doesn't improve, parts of this portfolio, which has underperformed its peers, could be on the block.
Sub-units within Neuroscience: While neuroscience is a high-growth area, specific sub-units with lower profit margins could face scrutiny.
The next significant milestone will be the Medtronic investor day in mid-2026, where the company will detail the work of the new committees and likely provide more information on its long-term strategy.